Page 45 - BH-2-4
P. 45
Brain & Heart Transforming transthyretin cardiac amyloidosis
Figure 1. Preferred reporting items for systematic reviews and meta-analyses chart
improvements in mortality, with a smaller magnitude, patients with less severe HF. The mortality benefits across
likely reflecting the more advanced nature of their disease. different subtypes and severities of ATTR-CM validate
This finding emphasizes an important point. If tafamidis is that tafamidis is a versatile and essential therapy for this
initiated earlier, the outcomes may be better, particularly in heterogeneous condition.
Volume 2 Issue 4 (2024) 5 doi: 10.36922/bh.4250
